# Opdivo® (nivolumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nivolumab

> The FDA approved Opdivo® (nivolumab), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on August 6, 2026 for with unresectable advanced cutaneous melanoma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Opdivo® (nivolumab) FDA approved?

Yes. The FDA approved Opdivo® (nivolumab), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on August 6, 2026 for with unresectable advanced cutaneous melanoma. SEC prospectus (424B): "On August 6, 2026, we announced that the FDA has granted accelerated approval of TUDRIQEV in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen." [Calendar and source filings](https://sec-api.dev/pdufa/nivolumab)

Source: SEC prospectus (424B), accession 0001104659-26-093040, https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm (retrieved 2026-11-12). Last confirmed 2026-10-28. Cite: https://sec-api.dev/pdufa/nivolumab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Opdivo® (nivolumab) |
| Codes | BMS-936558, BMS-936558-01, BMS-986298 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | advanced melanoma in patients, [advanced melanoma](https://sec-api.dev/indications/advanced-melanoma), [with unresectable advanced cutaneous melanoma](https://sec-api.dev/indications/with-unresectable-advanced-cutaneous-melanoma), advanced melanoma in july 2025, treatment-na&iuml, [Non-small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Clear Cell Renal Cell Carcinoma](https://sec-api.dev/indications/clear-cell-renal-cell-carcinoma), Mesothelioma, Malignant |
| Modality | antibody |
| FDA designations | accelerated, breakthrough, fast track, priority review |

## Timeline

### March 10, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-78 (Efficacy): submission_status AP, submission_status_date 20200310, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### May 15, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-80 (Efficacy): submission_status AP, submission_status_date 20200515, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### May 26, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-82 (Efficacy): submission_status AP, submission_status_date 20200526, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### June 10, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-81 (Efficacy): submission_status AP, submission_status_date 20200610, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### September 18, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-85 (Efficacy): submission_status AP, submission_status_date 20200918, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22
- openFDA Drugs@FDA: "BLA125554 SUPPL-84 (Efficacy): submission_status AP, submission_status_date 20200918, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### October 2, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-89 (Efficacy): submission_status AP, submission_status_date 20201002, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### January 22, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-90 (Efficacy): submission_status AP, submission_status_date 20210122, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### April 16, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-91 (Efficacy): submission_status AP, submission_status_date 20210416, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### May 20, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-92 (Efficacy): submission_status AP, submission_status_date 20210520, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### July 15, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-99 (Efficacy): submission_status AP, submission_status_date 20210715, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### August 19, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-97 (Efficacy): submission_status AP, submission_status_date 20210819, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### March 4, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-112 (Efficacy): submission_status AP, submission_status_date 20220304, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### May 11, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-108 (Efficacy): submission_status AP, submission_status_date 20220511, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### May 27, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-105 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22
- openFDA Drugs@FDA: "BLA125554 SUPPL-106 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### July 14, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-114 (Efficacy): submission_status AP, submission_status_date 20220714, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### February 15, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-119 (Efficacy): submission_status AP, submission_status_date 20230215, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22
- openFDA Drugs@FDA: "BLA125554 SUPPL-117 (Efficacy): submission_status AP, submission_status_date 20230215, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22
- openFDA Drugs@FDA: "BLA125554 SUPPL-118 (Efficacy): submission_status AP, submission_status_date 20230215, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### Jun 2023: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-01-29, last confirmed 2026-03-19.
- SEC prospectus (424B) (accession 0001104659-25-102602): "We reported positive topline safety and efficacy data from this study in June 2023 and positive follow-up immune response and survival data in December 2023." https://www.sec.gov/Archives/edgar/data/1390478/000110465925102602/tm2529505d2_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-007097): "We reported positive topline safety and efficacy data from this study in June 2023 and positive follow-up immune response and survival data in December 2023." https://www.sec.gov/Archives/edgar/data/1390478/000110465925007097/tm254790d2_424b5.htm
- SEC Form 10-K (accession 0001390478-26-000003): "In June 2023, we reported positive topline safety and efficacy data from the study:" https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm
- SEC Form 10-K (accession 0001390478-25-000003): "In June 2023, we reported positive topline safety and efficacy data from the study:" https://www.sec.gov/Archives/edgar/data/1390478/000139047825000003/sls-20241231.htm

### October 13, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-121 (Efficacy): submission_status AP, submission_status_date 20231013, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### January 26, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-122 (Efficacy): submission_status AP, submission_status_date 20240126, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### March 6, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-125 (Efficacy): submission_status AP, submission_status_date 20240306, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### 2H 2024: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2024-11-12, last confirmed 2024-11-26.
- SEC prospectus (424B) (accession 0001104659-24-123188): "Topline primary data from RP1 in combination with nivolumab in anti-PD-1 failed melanoma patients is expected in the second quarter of 2024 and we plan to submit a BLA for this cohort in the second half of 2024." https://www.sec.gov/Archives/edgar/data/1737953/000110465924123188/tm2429370-4_424b5.htm
- SEC prospectus (424B) (accession 0001104659-24-122298): "Topline primary data from RP1 in combination with nivolumab in anti-PD-1 failed melanoma patients is expected in the second quarter of 2024 and we plan to submit a BLA for this cohort in the second half of 2024." https://www.sec.gov/Archives/edgar/data/1737953/000110465924122298/tm2429370-2_424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116413): "Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus nivolumab in anti-PD1 failed melanoma via the accelerated approval pathway before the end of the year" https://www.sec.gov/Archives/edgar/data/1737953/000110465924116413/tm2428095d1_ex99-1.htm

### September 26, 2024: FDA advisory committee meeting

- Status: completed. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The Committee will discuss the existing supplemental biologics license applications (sBLA) which were approved for patients with previously untreated HER2-negative unresectable or metastatic gastric or gastroesophageal adenocarcinoma: sBLA 125554/S-091 for OPDIVO (nivolumab) injection, submitted by Bristol Myers-Squibb Co. and sBLA 125514/S-143 for KEYTRUDA (pembrolizumab) injection, submitted by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc." https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024

### October 3, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-127 (Efficacy): submission_status AP, submission_status_date 20241003, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### March 17, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1/2.
- First seen 2025-03-17, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-039826): "Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma" https://www.sec.gov/Archives/edgar/data/728387/000095017025039826/catx-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-069314): "On March 17, 2025, we announced that the first patient was dosed in the combination cohort, and on April 11, 2025, we announced that the first patient was dosed in the monotherapy cohort." https://www.sec.gov/Archives/edgar/data/728387/000095017025069314/catx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-045242): "On March 17, 2025, we announced that the first patient was dosed in the combination cohort." https://www.sec.gov/Archives/edgar/data/728387/000095017025045242/catx-20241231.htm

### April 8, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-132 (Efficacy): submission_status AP, submission_status_date 20250408, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22
- openFDA Drugs@FDA: "BLA125554 SUPPL-129 (Efficacy): submission_status AP, submission_status_date 20250411, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### May 22, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Extensive-stage Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04702880 (A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-06-17." https://clinicaltrials.gov/study/NCT04702880

### May 23, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-133 (Efficacy): submission_status AP, submission_status_date 20250523, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1. Indication: treatment-na&iuml.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126726): "Topline data from the on-going Phase 1b study evaluating givastomig in combination with nivolumab plus chemotherapy are expected in 2H 2025 in patients with treatment-na&iuml;ve CLDN 18.2-positive metastatic gastric cancer." https://www.sec.gov/Archives/edgar/data/1778016/000095017024126726/imab-ex99_1.htm

### July 21, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: advanced melanoma in July 2025.
- First seen 2025-11-06, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107438): "The resubmission is considered by the FDA to be a complete response to the complete response letter received on July 21, 2025." https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_ex99-1.htm
- SEC Form 10-Q (accession 0001628280-26-057099): "In July 2025, we received the first of two CRLs on our BLA for TUDRIQEV in combination with nivolumab for advanced melanoma patients, with the second CRL being issued by the FDA in April 2026." https://www.sec.gov/Archives/edgar/data/1737953/000162828026057099/repl-20260630.htm
- SEC prospectus (424B) (accession 0001104659-26-093040): "In July 2025, we received the first of two CRLs on our BLA for RP1 in combination with nivolumab for advanced melanoma patients, with the second CRL being issued by the FDA in April 2026." https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm
- SEC Form 10-K (accession 0001628280-26-045886): "For example, in July 2025, we received a CRL from the FDA in connection with our BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- SEC Form 10-Q (accession 0001628280-26-004805): "We received a CRL from the FDA in respect of our BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma in July 2025." https://www.sec.gov/Archives/edgar/data/1737953/000162828026004805/repl-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-049884): "We received a CRL from the FDA in respect of our BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma in July 2025." https://www.sec.gov/Archives/edgar/data/1737953/000162828025049884/repl-20250930.htm

### July 22, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-02-12, last confirmed 2025-05-22.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-011851): "Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025" https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-051847): "The FDA recently completed their late-cycle review and manufacturing inspections for the biologics license application, which remains on schedule ahead of a July 22, 2025 PDUFA date." https://www.sec.gov/Archives/edgar/data/1737953/000110465925051847/tm2515645d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-011851): ""With Priority Review and a PDUFA date set for July 22, 2025, by the FDA, our efforts are focused on ensuring a successful commercial launch of RP1 upon approval." https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-011851): "Priority Review by the FDA with a PDUFA action date of July 22, 2025." https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107438): "The resubmission is considered by the FDA to be a complete response to the complete response letter received on July 21, 2025." https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_ex99-1.htm

### July 29, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Clear Cell Renal Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04810078 (A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-09-22." https://clinicaltrials.gov/study/NCT04810078

### October 20, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: advanced melanoma in patients.
- First seen 2025-10-20, last confirmed 2026-08-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-100605): "WOBURN, Mass., October 20, 2025 - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen." https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_ex99-1.htm
- SEC prospectus (424B) (accession 0001104659-26-093040): "On October 20, 2025 we announced that the FDA had accepted the resubmission of the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen." https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm
- SEC Form 10-K (accession 0001628280-26-045886): "On October 20, 2025 we announced that the FDA had accepted the resubmission of the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- SEC Form 10-Q (accession 0001628280-26-004805): "On October 20, 2025 we announced that the FDA had accepted the resubmission of the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen." https://www.sec.gov/Archives/edgar/data/1737953/000162828026004805/repl-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-049884): "On October 20, 2025, the Company announced that the FDA had accepted the resubmission of the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on anti-PD-1 containing regimen." https://www.sec.gov/Archives/edgar/data/1737953/000162828025049884/repl-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-049884): "On October 20, 2025 we announced that the FDA had accepted the resubmission of the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen." https://www.sec.gov/Archives/edgar/data/1737953/000162828025049884/repl-20250930.htm
- SEC Form 10-K (accession 0001628280-26-045886): "Following discussions with the agency, in October 2025, the FDA accepted our resubmission of the BLA for RP1." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- SEC Form 10-Q (accession 0001628280-26-004805): "Following discussions with the agency, in October 2025, the FDA accepted our resubmission of the BLA for RP1." https://www.sec.gov/Archives/edgar/data/1737953/000162828026004805/repl-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-049884): "Following discussions with the agency, in October 2025 the FDA accepted our resubmission of the BLA for RP1." https://www.sec.gov/Archives/edgar/data/1737953/000162828025049884/repl-20250930.htm

### November 12, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Mesothelioma, Malignant.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05136677 (A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05136677

### Dec 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2026-02-24, last confirmed 2026-04-30.
- SEC Form 10-Q (accession 0001628280-26-028902): "In December 2025, we initiated a Phase 1b trial, SYNERGY, with a planned enrollment of 30 patients with solid tumors to evaluate the efficacy and safety of treatment with nenocorilant plus nivolumab (a PD-1 checkpoint inhibitor)." https://www.sec.gov/Archives/edgar/data/1088856/000162828026028902/cort-20260331.htm
- SEC Form 10-K (accession 0001628280-26-011091): "In December 2025, we initiated a Phase 1b trial, SYNERGY, with a planned enrollment of 30 patients with solid tumors to evaluate the efficacy and safety of treatment with nenocorilant plus nivolumab (a PD-1 checkpoint inhibitor)." https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-06-02, last confirmed 2025-08-20.
- Press release filed with the SEC (EX-99) (accession 0001778016-25-000009): "The Company expects to present topline data in Q1 2026." https://www.sec.gov/Archives/edgar/data/1778016/000177801625000009/imab-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-092603): "topline data expected in Q1 2026 Strong Capital Position with Cash Through Major Readouts $168.6M of cash as of March 31, 20254" https://www.sec.gov/Archives/edgar/data/1778016/000095017025092603/imab-ex99_3.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-080015): "topline data expected in 1H 2026 Strong Capital Position with Cash Through Major Readouts $168.6M of cash as of March 31, 20253" https://www.sec.gov/Archives/edgar/data/1778016/000095017025080015/imab-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001778016-25-000004): "Topline results expected in Q1 2026" https://www.sec.gov/Archives/edgar/data/1778016/000177801625000004/imab-ex99_1.htm

### February 16, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Urinary Bladder Neoplasms; Muscle-Invasive Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03661320 (A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-16 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT03661320

### March 20, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125554 SUPPL-135 (Efficacy): submission_status AP, submission_status_date 20260320, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22

### April 10, 2026: PDUFA date

- Status: completed, complete response letter. Date confidence: exact. Indication: advanced melanoma.
- First seen 2025-10-20, last confirmed 2026-08-10.
- SEC Form 8-K (accession 0001104659-25-100605): "The PDUFA date set by the FDA is April 10, 2026 based on a Class II resubmission timeline." https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107438): "2025, that the U.S. Food and Drug Administration (FDA) has accepted the BLA resubmission of RP1 for the treatment of advanced melanoma with a Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026." https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_ex99-1.htm
- SEC prospectus (424B) (accession 0001104659-26-093040): "The FDA indicated that the resubmission is considered to be a complete response to the CRL and set a PDUFA date of April 10, 2026 based on a Class II resubmission timeline." https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm
- SEC Form 10-K (accession 0001628280-26-045886): "The FDA indicated that the resubmission is considered to be a complete response to the CRL and set a target action date of April 10, 2026 based on a Class 2 resubmission timeline." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- SEC Form 10-Q (accession 0001628280-26-004805): "The FDA indicated that the resubmission is considered to be a complete response to the CRL and set a PDUFA date of April 10, 2026 based on a Class II resubmission timeline." https://www.sec.gov/Archives/edgar/data/1737953/000162828026004805/repl-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-049884): "The PDUFA date set by the FDA is April 10, 2026 based on a Class II resubmission timeline." https://www.sec.gov/Archives/edgar/data/1737953/000162828025049884/repl-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-049884): "The FDA indicated that the resubmission is considered to be a complete response to the CRL and set a PDUFA date of April 10, 2026 based on a Class II resubmission timeline." https://www.sec.gov/Archives/edgar/data/1737953/000162828025049884/repl-20250930.htm
- SEC Form 10-K (accession 0001628280-26-045886): "On April 10, 2026 the Company received a CRL from the FDA for the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm

### April 10, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: advanced melanoma.
- First seen 2026-04-13, last confirmed 2026-10-28.
- SEC Form 10-K (accession 0001628280-26-045886): "On April 10, 2026 the Company received a CRL from the FDA for the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-042141): "Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the" https://www.sec.gov/Archives/edgar/data/1737953/000110465926042141/tm2611633d1_ex99-1.htm
- SEC Form 10-K (accession 0001628280-26-045886): "On April 10, 2026, the FDA issued a second CRL in connection with our BLA for RP1 for the treatment of advanced melanoma." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- SEC Form 10-Q (accession 0001628280-26-067722): "Following the second CRL issued by the FDA on April 10, 2026 for the Company's RP1 BLA for the treatment of advanced melanoma, the Lead Plaintiff filed a second amended complaint in the class action that addresses the second CRL." https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-057099): "Following the second CRL issued by the FDA on April 10, 2026 for the Company's RP1 BLA for the treatment of advanced melanoma, the Lead Plaintiff filed a second amended complaint in the class action that addresses the second CRL." https://www.sec.gov/Archives/edgar/data/1737953/000162828026057099/repl-20260630.htm
- SEC Form 10-K (accession 0001628280-26-045886): "On April 10, 2026 the FDA issued a second CRL to our BLA for RP1 for the treatment of advanced melanoma." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- SEC Form 10-K (accession 0001628280-26-045886): "Following the second CRL issued by the FDA on April 10, 2026 for the Company's RP1 BLA for the treatment of advanced melanoma, the Lead Plaintiff filed a second amended complaint in the class action that addresses the second CRL." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- SEC Form 10-Q (accession 0001628280-26-067722): "Sales and marketing costs were put on hold after the Company received a complete response letter in April 2026 from the FDA and did not resume until late in the second quarter of this fiscal year." https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-067722): "•we have no prior experience in marketing, selling and distributing TUDRIQEV or any other product; following receipt of a second CRL in April 2026, we implemented significant cost-savings measures, including significant reductions in force in our in-house sales, marketing or commercialization teams; although we have begun to rebuild these capabilities in advance of commercializing TUDRIQEV, we may face challenges in rehiring former staff or hiring, training, and deploying new staff to meet our commercialization objectives;" https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-057099): "•we have no prior experience in marketing, selling and distributing TUDRIQEV or any other product; following receipt of a second CRL in April 2026, we implemented significant cost-savings measures, including significant reductions in force in our in-house sales, marketing or commercialization teams; although we have begun to rebuild these capabilities in advance of commercializing TUDRIOEV, we may face challenges in rehiring former staff or hiring, training, and deploying new staff to meet our commercialization objectives;" https://www.sec.gov/Archives/edgar/data/1737953/000162828026057099/repl-20260630.htm
- SEC prospectus (424B) (accession 0001104659-26-093040): "following receipt of a second CRL in April 2026, we implemented significant cost-savings measures, including significant reductions in force in our in-house sales, marketing or commercialization teams; although we have begun to rebuild these capabilities in advance of commercializing TUDRIQEV, we may face challenges in rehiring former staff or hiring, training, and deploying new staff to meet our commercialization objectives;" https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm

### May 27, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hepatocellular Carcinoma; Liver Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03383458 (A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-27 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT03383458

### June 17, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Extensive-stage Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04702880 (A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-06-17." https://clinicaltrials.gov/study/NCT04702880?tab=results

### June 26, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-06-26, last confirmed 2026-06-29.
- SEC Form 10-K (accession 0001628280-26-045886): "On June 26, 2026 we announced the FDA accepted the BLA resubmission as a Class 1 resubmission with an action date of August 2, 2026." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-078009): "Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for" https://www.sec.gov/Archives/edgar/data/1737953/000110465926078009/tm2619037d1_ex99-1.htm

### July 9, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04039607 (A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-09 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT04039607

### August 2, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2026-06-29, last confirmed 2026-06-29.
- SEC Form 10-K (accession 0001628280-26-045886): "On June 26, 2026 we announced the FDA accepted the BLA resubmission as a Class 1 resubmission with an action date of August 2, 2026." https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm
- SEC prospectus (424B) (accession 0001104659-26-093040): "On August 6, 2026, we announced that the FDA has granted accelerated approval of TUDRIQEV in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen." https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm

### August 6, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with unresectable advanced cutaneous melanoma.
- First seen 2026-08-07, last confirmed 2026-10-28.
- SEC prospectus (424B) (accession 0001104659-26-093040): "On August 6, 2026, we announced that the FDA has granted accelerated approval of TUDRIQEV in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen." https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-092246): "Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous" https://www.sec.gov/Archives/edgar/data/1737953/000110465926092246/tm2622487d1_ex99-1.htm
- SEC Form 10-Q (accession 0001628280-26-067722): "In August 2026, we received FDA approval to commercialize TUDRIQEV in combination with nivolumab in the U.S. for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression with an anti-PD-1 antibody-based regimen, and we are commercially launching TUDRIQEV in the U.S. in that indication." https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-067722): "Following the issuance of two CRLs in respect of our BLA for TUDRIQEV, in August 2026, we received FDA approval to commercialize TUDRIQEV in combination with nivolumab in the U.S. for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression with an anti-PD-1 antibody-based regimen, and we are preparing to initiate a commercial launch of TUDRIQEV in the U.S. in that indication." https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm

### September 22, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Clear Cell Renal Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04810078 (A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-09-22." https://clinicaltrials.gov/study/NCT04810078?tab=results

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06946797 (A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06946797

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06946797 (A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06946797

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Renal Cell Carcinoma.
- First seen 2026-02-17, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03873402 (A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT03873402
- Press release filed with the SEC (EX-99) (accession 0001193125-26-054569): "Top line Phase 2 results are expected in 2027." https://www.sec.gov/Archives/edgar/data/1778016/000119312526054569/nbp-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-054569): "Top line results from the Phase 2 study are expected in 2027" https://www.sec.gov/Archives/edgar/data/1778016/000119312526054569/nbp-ex99_1.htm

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Renal Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03873402 (A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT03873402

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03899155 (Pan Tumor Rollover Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-25 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT03899155

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03899155 (Pan Tumor Rollover Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-25 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT03899155

### Jul to Oct 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06561386 (A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-30 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06561386

### July 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06561386 (A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-30 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06561386

### Nov 2030 to Feb 2031: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221149 (A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-11-08 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07221149

### November 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221149 (A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-11-08 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07221149

## Same indication

- [89zr-tlx250 pet/ct](https://sec-api.dev/pdufa/89zr-tlx250-pet-ct) (TLX)
- [Calderasib](https://sec-api.dev/pdufa/calderasib) (MRK)
- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan) (AZN)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [LBL-007](https://sec-api.dev/pdufa/lbl-007) (ONC)
- [Amtagvi® (lifileucel)](https://sec-api.dev/pdufa/lifileucel) (IOVA)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib) (HCM)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab) (ONC)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [Vusolimogene oderparepvec](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) (REPL)
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab) (GILD)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02), [March 2027](https://sec-api.dev/fda-calendar/2027-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nivolumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Opdivo® (nivolumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nivolumab

```bibtex
@misc{secapidev_pdufa_nivolumab_20261116,
  title        = {Opdivo® (nivolumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nivolumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nivolumab_20261116","title":"Opdivo® (nivolumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nivolumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
